Older individuals between the ages of 75 and 80 who are eligible for lung surgery may achieve survival outcomes comparable to younger patients following lung cancer screening, according to research presented today at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer (WCLC).
Despite half of lung cancers being diagnosed in people aged 75 or older, randomised evidence on screening outcomes in this age group is limited.
Most national lung cancer screening programmes, including the UK’s, stop at age 74.
The U.S. Preventive Services Task Force recommends screening up to age 80, although little was known about how much benefit is achieved by extending the upper age limit to 80.
This study compared outcomes between patients aged 55–74 and those aged 75–80 diagnosed with screen-detected lung cancer in two UK targeted lung cancer screening programmes.
The Yorkshire Lung Screening Trial (YLST) and the North & East Manchester Lung Health Check (NEM-LHC) programme systematically invited people with a history of smoking beginning in 2019.
Researchers analysed clinical data from 574 invasive lung cancer cases, of which 190 (33%) were in the 75–80 age group.
Stage distribution was similar between age groups.
Curative-intent treatment rates were high overall (87%), but surgical resection rates were lower in the older group (42% vs.58%, p<0.001).
All-cause mortality was higher among those aged 75–80 (HR 1.54, 95% CI 1.12–2.10), with mortality at four years being 44% versus 34%.
However, in patients treated with surgery, survival rates were comparable between age groups (16% vs.18% mortality at four years; HR 1.00).
“Our findings suggest that extending lung cancer screening up to age 80 could be valuable for older adults who are fit for surgery,” said Patrick Goodley, Manchester University NHS Foundation Trust, United Kingdom.
“Screening selection incorporating surgical fitness, rather than age alone, may allow us to deliver curative treatment to more people with lung cancer.”
Source: International Association for the Study of Lung Cancer
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.